FDA prioritizes thyroid eye disease medication review

The FDA on Monday granted priority review of the investigational medication teprotumumab for treatment of thyroid eye disease, also known as Graves’ orbitopathy according to a press release from Horizon Therapeutics.
“Priority review for the teprotumumab [biologics license application] is another positive step toward our goal to make a difference in the lives of people who are living with active [thyroid eye disease] — a painful, debilitating and vision-threatening rare disease,” Timothy Walbert, chairman, president and CEO of Horizon Therapeutics, said in the release. “The

Full Story →